Compliance certificate for Q2 FY27 demat details filed

Compliance View source PDF Explain this filing

PGHL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.1%Reaction day

₹5300.00

prior close

₹5206.00

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.2%-0.9% vs market

Pharmaceuticals peers, median of 170sector-0.3%-0.8% vs sector

On the reaction day the stock moved 0.9 pts less than Nifty Microcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.2

15m

+0.3

30m

+0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.1-0.2-0.9-0.3-0.8

Next day

-2.4-3.0+0.6-2.7+0.3

-1.2-2.7+1.5-2.7+1.5

-2.6-1.9-0.7-2.6+0.0

+0.5-1.7+2.2-3.1+3.6

-1.2-1.0-0.1-3.0+1.8

-2.1-2.0-0.1-3.5+1.5

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Procter & Gamble Health has submitted a compliance certificate under SEBI Regulation 74(5) for the quarter ended September 30, 2026. The certificate, issued by registrar Kfin Technologies, confirms that details of securities dematerialized and rematerialized during the quarter have been furnished to NSE and BSE within the prescribed timeline. This is a routine quarterly regulatory filing and does not involve any corporate action or change in shareholding structure.

Likely market impact

Routine procedural compliance filing with no impact on shareholders or stock price.